Profile data is unavailable for this security.
About the company
Organovo Holdings, Inc. is a clinical-stage biotechnology company. The Company is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
- Revenue in USD (TTM)103.00k
- Net income in USD-12.54m
- Incorporated2012
- Employees12.00
- LocationOrganovo Holdings IncSuite 100, 11555 Sorrento Valley RoadSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 224-1000
- Fax+1 (302) 636-5454
- Websitehttps://organovo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepion Pharmaceuticals Inc | 0.00 | -22.70m | 4.80m | 22.00 | -- | -- | -- | -- | -4.47 | -4.47 | 0.00 | -0.0585 | 0.00 | -- | -- | 0.00 | -158.12 | -61.43 | -231.68 | -68.82 | -- | -- | -- | -- | -- | -58.74 | 1.24 | -- | -- | -- | -7.92 | -- | -- | -- |
| Correlate Energy Corp | 5.65m | -34.51m | 4.81m | 19.00 | -- | -- | -- | 0.8521 | -0.8359 | -0.8359 | 0.1457 | -0.0461 | 1.50 | -- | 11.12 | 297,377.40 | -915.61 | -315.47 | -- | -- | -6.45 | 15.42 | -610.79 | -201.03 | -- | -1.33 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.00m | 4.86m | 0.00 | -- | -- | -- | -- | -0.0536 | -0.0536 | 0.00 | -0.0329 | 0.00 | -- | -- | -- | -441.41 | -- | -- | -- | -- | -- | -- | -- | -- | -46.71 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -24.01m | 4.94m | 40.00 | -- | 1.03 | -- | -- | -24.54 | -23.96 | 0.00 | 0.2592 | 0.00 | -- | -- | 0.00 | -113.61 | -47.16 | -162.49 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
| Carmell Corp | -3.70m | -7.34m | 5.18m | 9.00 | -- | -- | -- | -- | -1.16 | -1.08 | -0.1956 | -0.1944 | -0.0873 | 0.001 | 0.0046 | -410,664.40 | -17.34 | -- | -35.99 | -- | 84.38 | -- | -- | -- | 0.2895 | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.26m | -942.61k | 5.24m | 30.00 | -- | 0.5587 | -- | 0.5664 | -0.0391 | -0.0391 | 0.584 | 0.5225 | 0.8245 | 6.42 | 7.96 | -- | -8.39 | -3.83 | -9.72 | -5.02 | 13.47 | 14.55 | -10.18 | -3.04 | 3.99 | -- | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
| Enzon Pharmaceuticals Inc | 26.00k | 247.00k | 5.28m | 0.00 | 21.35 | 1.91 | -- | 202.95 | 0.0033 | 0.0033 | 0.0004 | 0.6311 | 0.0006 | -- | -- | -- | 3.23 | -0.8654 | 3.26 | -0.8851 | -- | -- | 5,853.85 | -159.43 | -- | -- | 0.00 | -- | -100.00 | -- | 106.71 | -55.86 | -- | -- |
| Tron Pharmaceuticals Inc | 1.01m | -549.47k | 5.29m | 50.00 | -- | -- | -- | 5.24 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Organovo Holdings Inc | 103.00k | -12.54m | 5.38m | 12.00 | -- | 1.46 | -- | 52.20 | -1.07 | -1.07 | 0.008 | 0.2395 | 0.0115 | -- | 2.45 | 5,150.00 | -140.02 | -54.25 | -180.45 | -58.42 | 64.08 | -- | -12,176.70 | -1,890.16 | 1.72 | -- | 0.0947 | -- | -70.54 | -48.78 | 15.00 | -- | -11.87 | -- |
| Clearmind Medicine Inc | 0.00 | -8.44m | 5.44m | -- | -- | 1.54 | -- | -- | -12.73 | -12.73 | 0.00 | 0.8728 | 0.00 | -- | -- | -- | -133.31 | -218.20 | -266.82 | -488.96 | -- | -- | -- | -- | -- | -2.60 | 0.0172 | -- | -- | -- | -25.03 | -- | -- | -- |
| Kineta Inc | 0.00 | -17.28m | 5.50m | 11.00 | -- | -- | -- | -- | -1.47 | -1.47 | 0.00 | -0.7914 | 0.00 | -- | -- | 0.00 | -267.71 | -66.16 | -- | -86.61 | -- | -- | -- | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
| Klotho Neurosciences Inc | 0.00 | -744.61k | 5.57m | -- | -- | -- | -- | -- | -0.0255 | -0.0255 | 0.00 | -0.099 | 0.00 | -- | -- | -- | -2.46 | -- | -2.56 | -- | -- | -- | -- | -- | -- | -- | 1.66 | -- | -- | -- | 9.14 | -- | -- | -- |
| Alzamend Neuro Inc | 0.00 | -7.39m | 5.82m | 4.00 | -- | -- | -- | -- | -10.69 | -10.69 | 0.00 | -1.41 | 0.00 | -- | -- | 0.00 | -344.10 | -177.86 | -- | -257.81 | -- | -- | -- | -- | -- | -363.62 | -- | -- | -- | -- | 33.14 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.06m | 5.84m | 1.00 | -- | -- | -- | -- | -0.0017 | -0.0017 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -32.46 | -- | -46.53 | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | -- | -- | -14.64 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Organovo Holdings Inc's reporting currency: US Dollar USD
15.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Sep 2024 | 1.22m | 7.93% |
| Prescott Group Capital Management LLCas of 30 Sep 2024 | 414.04k | 2.70% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 347.49k | 2.26% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 142.21k | 0.93% |
| Geode Capital Management LLCas of 30 Sep 2024 | 125.48k | 0.82% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 44.03k | 0.29% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 27.83k | 0.18% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 24.81k | 0.16% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Sep 2024 | 19.62k | 0.13% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 18.71k | 0.12% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
